3200威尼斯vip(中国)有限公司

News
NEWS
Home News Industry News
China's first expert consensus on cervical cancer screening released! HPV nucleic acid primary screening strongly recommended!
2023-10-20

China is in a critical period of accelerating the elimination of cervical cancer, and using high-quality screening methods to improve screening coverage is one of the main means to eliminate cervical cancer.


Human papillomavirus (HPV) nucleic acid testing is the preferred method recommended by WHO for primary cervical cancer screening, but China has no guiding document for its use in cervical cancer screening practice.


Therefore,the Tumor Prevention and Control Professional Committee of the Chinese Preventive Medicine Association and the Chinese Medical Journal invited more than 50 domestic experts in multiple disciplines including public health, obstetrics and gynecology, laboratory medicine, and pathology to develop an expert consensus based on domestic and international guidelines, medical evidence, and China's actual conditions。


targeting public health personnel, maternal and child health personnel, obstetrics and gynecology clinicians, laboratory testing personnel, and others involved in cervical cancer screening, aiming to standardize the practice of HPV nucleic acid testing for cervical cancer screening, develop consensus opinions that suit China's national conditions and guide grassroots practice, promote comprehensive, in-depth, standardized, and orderly high-quality development of HPV nucleic acid testing in China, and provide strong support for achieving the goal of cervical cancer elimination in China.





From April 28 to 30, the National Cervical Cancer Collaborative Group Work Conference concluded in Beijing. At the conference, the consensus was officially released for the first time, and Professor Bi Hui provided a professional interpretation.


The consensus provides detailed elaboration and recommendations from multiple perspectives including HPV types and risk stratification, persistent infection, detection technologies, laboratory quality assurance, selection of nucleic acid testing systems, related support requirements, application of nucleic acid testing, operational procedures, monitoring and evaluation, and highlighted the following content:

  • Typing detection of HPV and clarification of whether persistent infection exists have important clinical significance;

  • E6/E7 DNA, as oncogenes, will integrate with host DNA during persistent infection;

  • Long-term follow-up of high-risk type positivity as a key management strategy.


Main consensus recommendations & interpretation




Recommendation 1


For HR-HPV nucleic acid testing positive individuals, follow the principle of "equal risk, equal management" for stratified management. HPV16/18 are the types with the highest carcinogenic risk and require timely referral to colposcopy for further evaluation. For other HR-HPV infected individuals, more evidence of pathogenic risk needs to be accumulated and the effectiveness of triage evaluated, so as to propose appropriate triage strategies.

HR-HPV persistently infected individuals have an increased risk of cervical precancerous lesions and cervical cancer, and a more active management strategy is recommended.



Interpretation 1


For HR-HPV nucleic acid testing positive individuals, follow the principle of "equal risk, equal management" for stratified management; HPV16/18 require timely referral to colposcopy for further evaluation.HR-HPV persistently infected individuals require special attention.







Recommendation 2


HPV nucleic acid testing methods can be divided into non-amplification methods and amplification methods, which can effectively detect the entire HPV genome or a certain fragment (for example: using L1 DNA, E6/E7 DNA, or mRNA as detection targets).


Interpretation 2


E6/E7 DNA, as oncogenes, will integrate with host DNA during persistent infection.PCR-capillary electrophoresis using E6/E7 DNA as the target can perform typing detection of different types.










Recommendation 3


HPV nucleic acid testing laboratories should develop relevant documents and management systems regarding environment, safety, personnel, instruments and equipment, and reagents and consumables, establish standard operating procedures covering the entire testing process, and improve quality control procedures.

It is recommended to select HPV nucleic acid testing reagents or testing systems approved by NMPA and validated through laboratory analytical performance verification;When HPV nucleic acid testing reagents or testing systems are used for clinical cervical cancer screening, clinical performance needs to be verified to assess whether they meet the intended clinical use.


Interpretation 3


For testing reagents or systems used in clinical cervical cancer screening,Requires NMPA approval and validation of clinical performance.







Recommendation 4


Screening population: ① Prioritize screening for women aged 35-64; ② Include in routine physical examinations where conditions permit; it is also recommended to follow this recommendation in employer-organized physical examinations.

Screening method: HR-HPV testing is recommended as the preferred method for population-based cervical cancer screening, with a screening interval of 5 years.

Selection of HPV testing methods: ① Detect at least 13 types of HR-HPV (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68); ② Where conditions permit, at least HPV16/18 genotyping is recommended; ③ Use HPV testing methods that are NMPA-approved and have passed laboratory analytical performance validation and clinical performance validation.

For those who test HPV-positive during screening, further management recommendations should be determined based on their risk of developing HSIL+: ① Those positive for HPV16/18 should be directly referred for colposcopy; ② Those not positive for HPV16/18 are recommended to undergo triage testing (cytology or other methods), and those with positive triage results should be referred for colposcopy; ③ Those with persistent HR-HPV infection are recommended to be directly referred for colposcopy.





Recommendation 5


For those with cytology showing ASC-US, HPV nucleic acid testing is recommended as the preferred triage method, and whether colposcopy referral is needed should be determined based on triage results:

For those who test HPV-negative, retest after 3 years; in areas with relatively insufficient cytology diagnostic proficiency and cytology quality control, the retest interval may be 12 months;Those who test HPV-positive should be directly referred for colposcopy.





Recommendation 6


At 6 months after treatment for HSIL, the first surveillance should be performed using standalone HPV nucleic acid-based testing or co-testing with cytology; for those with negative results, annual HPV nucleic acid-based retesting should be performed for the following 3 years; for those with all negative results, the follow-up interval may be extended to once every 3 years for 25 years.

For AIS patients who have negative margins after cervical excisional treatment and desire to preserve fertility, fertility-sparing management may be pursued. It is recommended that cytology combined with HPV testing and endocervical evaluation be performed every 6 months for the first 3 years after surgery; for those with all negative results, cytology combined with HPV testing and endocervical evaluation may be performed annually for the following 2 years; for those with all negative results within 5 years, the follow-up interval may be further extended to once every 3 years for long-term follow-up.

For those who have undergone total hysterectomy and had prior HSIL+, it is recommended that cytology combined with HPV nucleic acid testing be performed annually for the first 3 years after surgery; for those with all negative results, the follow-up interval may be extended to once every 3 years for 25 years.


Interpretation of Recommendations 4 & 5 & 6


Prioritize screening for women aged 35-64; include in routine physical examinations where conditions permit;


HPV nucleic acid testing should include at least 13 types of HR-HPV; HPV16/18 genotyping is recommended where conditions permit;


Reagents and instruments must be NMPA-approved and validated;


Those with persistent HR-HPV infection are recommended to be directly referred for colposcopy. Full genotyping can efficiently identify persistent infection with different HPV types. The importance of full genotyping in HPV nucleic acid testing has been further elevated.



  





Recommendation 7


Populations receiving prophylactic HPV vaccination: It is recommended to adopt the same screening strategy as for unvaccinated populations.

Immunocompromised populations: ① HIV population: It is recommended to start screening within 1 year for women aged 25 or those who have begun sexual activity, with regular screening every 3-5 years; after positive screening results or treatment of cervical lesions, the screening interval should be shortened; the specific screening timing should be determined through discussion with specialists, and the screening frequency is usually twice that of the general population; ② Other immunocompromised populations: The same screening strategy as for the HIV-infected population may be followed.

Women preparing for pregnancy and pregnant women are recommended to adopt the same principles for screening and management as non-pregnant women.① Women who intend to become pregnant should be asked during preconception examination whether they have undergone cervical cancer screening within the past year; ② Women who have never been screened or have not been screened regularly should be screened during preconception examination or at the first prenatal visit; ③ For pregnant women with positive screening results, note the following: endocervical examination or endometrial curettage/biopsy must not be performed; excisional procedures are recommended only when cervical cancer is suspected; if relevant tests exclude HSIL+, it is recommended to defer re-examination until after delivery; if relevant tests suspect or diagnose CIN2 or CIN3, it is recommended to continue monitoring and defer re-evaluation or treatment until after delivery.

Women aged ≥65 years① Those who have not undergone regular screening in the past 10 years should continue screening; ② Those who have had 3 consecutive routine cytology examinations with no abnormal results or 2 consecutive routine HPV screening tests with negative results within 10 years, and who have no history of CIN, may stop screening.


Interpretation of Opinion 7


It is recommended that individuals who have received prophylactic HPV vaccination adopt the same screening strategy as those who have not received HPV vaccination.


The screening frequency for immunodeficient populations is twice that of the general population;


Women preparing for pregnancy and pregnant women are recommended to follow the same principles of screening and management as non-pregnant women;


Women aged ≥65 years who have had 3 consecutive routine cytology examinations with no abnormal results or 2 consecutive routine HPV screening tests with negative results within 10 years, and who have no history of CIN, may stop screening.



  



This consensus is a unanimous agreement formed by a multidisciplinary expert team based on relevant domestic and international guidelines, the latest research advances, and the actual situation of cervical cancer screening in China.This is the first time in an expert consensus that the use of oncogenes E6/E7 as detection targets and the PCR-capillary electrophoresis method for full-genotyping HPV nucleic acid detection have been mentioned.

With the development of technology and the accumulation of evidence-based evidence, it is necessary to continuously update and supplement consensus or guidelines. Applying high-quality HPV nucleic acid testing to cervical cancer screening will accelerate the process of translating clinical practice for cervical cancer screening in China from morphological to molecular biological testing, provide technical support for expanding the coverage rate of cervical cancer screening and improving screening quality in China, and accelerate the process of cervical cancer elimination in China.

Share to:
Products
Cell Biology
Molecular Biology
Liquid Handling
Bioprocessing
Custom Products
Solutions
Biopharmaceuticals
Cell & Gene Therapy
Vaccines
Diagnostics & Testing
About Us
Company Profile
Corporate Culture
Development History
Honors & Qualifications
Contact Us
Service Hotline: 400-800-6815
Email: info@cellprobio.net
Address: Building 40, No. 18 Dongchang Road, Suzhou Industrial Park
[WeChat Account QR Code]
Copyright © 2023 Suzhou CellPro Biotechnology Co., Ltd. All rights reserved. Record No.:Su ICP No. 19059453-1
Baidu
sogou